Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shattuck Labs, Inc. filings document the regulatory disclosures of a clinical-stage biotechnology company developing DR3-blocking antibodies for inflammatory and immune-mediated diseases. Its 8-K reports cover operating results, financial condition, clinical-program updates for SL-325, material agreements, and capital-structure matters involving its Nasdaq-listed common stock.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, stockholder proposal deadlines, board composition changes, and executive-compensation or equity-award topics. Registration and offering-related disclosures include common stock financing arrangements, Form S-3 materials, and at-the-market offering mechanics.
Shattuck Labs Chief Technical Officer Abhinav A. Shukla reported option-related trades in the company’s common stock. On June 30 and July 1, he exercised stock options covering a total of 23,465 shares at an exercise price of $3.57 per share.
The same total of 23,465 shares of common stock was sold in open-market transactions at weighted average prices of about $7.08 and $7.07 per share, under a pre-arranged Rule 10b5-1 trading plan intended to fund the option exercise price and estimated tax withholding. After these transactions, he directly holds 86,380 shares of common stock and continues to hold unexercised portions of an option covering up to 52,200 shares that vests through January 25, 2027.
Shattuck Labs, Inc. Chief Medical Officer Arundathy N. Pandite reported an open-market sale of 30,000 shares of common stock at a weighted average price of $7.01 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 2, 2026.
Following this sale, Pandite continues to hold 136,219 shares of Shattuck Labs common stock directly.
STTK filer reported a proposed sale of 410 shares of Common Stock via a stock option exercise to be sold for cash on 07/02/2026. The filing lists broker Fidelity Brokerage Services LLC.
The filing also discloses recent dispositions in the prior three months: 2,032 shares on 05/12/2026 for $14,235.58, 23,365 shares on 06/30/2026 for $165,468.59, and 100 shares on 07/01/2026 for $707.00.
Abhinav A. Shukla reports a proposed sale of 100 shares of Common Stock via a Form 144 notice dated 07/01/2026. The filing lists the transaction as a stock option exercise with cash used for payment.
The disclosure also shows prior sales during the past three months: 2,032 shares on 05/12/2026 with proceeds $14,235.58, and 23,365 shares on 06/30/2026 with proceeds $165,468.59. The broker/dealer listed is Fidelity Brokerage Services LLC.
STTK filing of a Rule 144 notice records an intended sale of Common stock tied to a Stock Option Exercise with a transaction date of 06/30/2026. The filing lists the broker Fidelity Brokerage Services LLC and shows numeric entries including 23365 and 14235.58 in the disclosure.
Shattuck Labs ownership filing: Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin report beneficial ownership of 5,000,033 shares of Common Stock, representing 5.17% of the class as reported in the cover data. The calculation uses 96,801,464 shares (based on 95,508,165 outstanding as of June 11, 2026 plus 1,293,299 Pre‑Funded Warrants). The Pre‑Funded Warrants are exercisable subject to a 9.99% ownership limitation.
Shattuck Labs director-associated funds increased their indirect stake through derivative securities. Entities affiliated with OrbiMed bought a total of 1,250,000 Pre-Funded Warrants for Shattuck Labs common stock on June 11, 2026, each with an exercise price of $0.0001 per share.
Following these purchases, one OrbiMed vehicle held 5,303,908 Pre-Funded Warrants and 1,051,021 common shares indirectly, while another held 26,519,541 Pre-Funded Warrants and 5,255,106 common shares indirectly. The warrants are exercisable after issuance, subject to a 9.99% beneficial ownership blocker.
Shattuck Labs, Inc. reported that investment entities affiliated with OrbiMed purchased pre-funded warrants linked to its June 2026 public offering. OrbiMed-related funds acquired pre-funded warrants exercisable for a total of 1,250,000 shares of common stock at an exercise price of $0.0001 per share, subject to a 9.99% beneficial ownership blocker. The public offering comprised 10,879,376 common shares at $4.00 per share and, in lieu of shares to certain investors, 7,870,624 pre-funded warrants at $3.9999 each. The securities are held of record by OrbiMed Private Investments IX, LP and OrbiMed Genesis Master Fund, L.P., while OrbiMed Advisors and its affiliated general partners may be deemed to share voting and investment power but disclaim beneficial ownership beyond their pecuniary interests.
OrbiMed Advisors LLC and affiliates filed Amendment No. 1 to their Schedule 13D on Shattuck Labs, Inc., updating their ownership and recent transaction details. The group reports beneficial ownership of 9,021,127 shares of common stock, representing 9.99% of Shattuck’s outstanding shares, largely through funds OPI IX and Genesis.
The filing describes a 2025 private placement where PIPE investors bought 15,225,158 shares, 37,410,188 2025 pre-funded warrants, and 52,635,346 common warrants, all subject to a 9.99% ownership “Blocker.” In June 2026, OrbiMed funds converted common warrants into additional pre-funded warrants and participated in a public offering that included new pre-funded warrants at $3.9999 per warrant. The pre-funded warrants carry a nominal $0.0001 exercise price and are exercisable subject to the Blocker.
Redmile Group, LLC and affiliated entities filed Amendment No. 5 to their Schedule 13D on Shattuck Labs, Inc. (STTK), updating their ownership and recent warrant activity. The reporting persons may be deemed to beneficially own 9,819,084 shares of common stock, representing 9.9% of the class.
This includes 7,038,119 shares of common stock held by Redmile funds and, subject to a 9.99% Beneficial Ownership Limitation, 10,943,951 shares issuable upon exercise of Pre-Funded Warrants, of which 2,780,965 shares are counted for beneficial ownership purposes. Redmile funds exercised Common and Pre-Funded Warrants in June 2026, paying about $4.44 million in aggregate exercise price and separately buying additional Pre-Funded Warrants in an underwritten offering for about $3.99 million.